AzTrials
AzTrials

H Pylori InfectionNCT03629587

Helicobacter Pylori and it's Hematological Impact

An observational study of H Pylori Infection, run by Assiut University.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To evaluate the effect of helicobacter pylori on the blood for proper management Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
H Pylori Infection
How many people
100 participants
Where
No sites listed yet
Study dates
27 Sep 2016to 8 Aug 2018
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • Adult, Older adult

Study population: 100 patients were presented with symptoms suggesting of gastritis, Group (A) 50 patients with positive H .Pylori biopsy, Group (B): 50 patients with negative H.pylori biopsy. All patients and control group were submitted to:1- Detailed history of age, sex, associate diseases, and family history of the same illness or others.2- Detailed history about gastric symptoms and duration of the disease 3-Full clinical examination 4- Laboratory investigations including: * Complete blood count with reticulocytic count.- Upper endoscopy - Diagnostic biopsy * Serum iron, total iron binding capacity and serum Ferritin.- Vitamin B 12 and folic acid level if indicated- Bone marrow aspirate if indicated.

Who may be able to join

  • All patients complained of symptoms suggestive of gastritis whether acute (within two weeks) or chronic (three or more months) and were diagnosed at endoscopy to have H.pylori infection by biopsy.
  • Patients aged more than 18 years old.
  • Both sexes (male \& female).

Who cannot join

  • Patients with malignant diseases or Gastric malignancy.
  • Other causes of Thrombocytopenia as systemic lupus erythematous and human immunodeficiency virus and or acquired immunodeficiency syndrome.
  • Other causes of Anemias with or without blood loss.

About this study

To evaluate the effect of helicobacter pylori on the blood for proper management

Read the detailed description

r pylori (H. pylori)is the most common infection in humans, with a marked disparity between developed and developing countries.It presents in over 50% of all stomachs in the world population, making it the most frequent infection in humanS. It displays a marked disparity in occurrence between developed countries, where its prevalence oscillates between 30% and 50%, and developing countries, where its prevalence ranges between 80% and 90%.

Although H. pylori infections are asymptomatic in most infected individuals, they are intimately related to malignant gastric conditions such as gastric cancer and gastric mucosa-associated lymphoid tissue (MALT) lymphoma and to benign diseases such as gastritis and duodenal and gastric peptic ulcers.

Since it was learned that bacteria could colonize the gastric mucosa, there have been reports in the medical literature of over 50 extragastric manifestations involving a variety medical areas of specialization. These areas include cardiology, dermatology, endocrinology, gynecology and obstetrics, hematology, pneumology, odontology, ophthalmology, otorhinolaryngology and pediatrics, and they encompass conditions with a range of clear evidence between the H. pylori infection and development of the disease.

This review focuses on hematologic diseases included in international consensus and management guides for H. pylori infection; specifically iron deficiency Anemia, vitamin B12 (cobalamin) deficiency, immune thrombocytopenia, and extranodal marginal zone mucosa-associated lymphoid tissue lymphoma (MALT Lymphoma). In addition of other hematologic diseases not included in guides and consensus as auto-immune neutropenia, antiphospholipid syndrome, and plasma cell dyscrasias.

Iron deficiency Iron deficiency (ID) is a serious public health issue, regardless of whether it is associated with anemia . It is especially important to remember that ID is a chronic process with a slow onset, in which the iron imbalance may take several years to establish and manifest clinically. One of the consequences can be observed through blood characteristics such as morphological alterations of erythrocytes or the presence of anemia, according to the criteria of the WHO.ID occurs in three stages: pre-latent (stage 1), in which ferritin is between 12 and 30 μg/L, latent (stage 2) when the ferritin falls below 12 μg/L, and ID anemia (stage 3) when anemia is present in addition to diminished or depleted reservoir iron levels (determined by serum ferritin).

Vitamin B12 deficiency Vitamin B12 is required as a coenzyme for the metabolism of the amino acids methionine, threonine and valine and for the transformation of methyl-tetrahydrofolate to tetrahydrofolate, which is necessary for DNA synthesis. Vitamin B12 deficiency, also known as cobalamin deficiency, is defined by low serum values of vitamin B12 and both homocysteine and methylmalonic acid (two components of the vitamin B12 metabolic pathway). Vitamin B12 deficiency occurs as a result of antibodies directed against gastric parietal cells and intrinsic factor, in addition to achlorhydria and a decrease in pepsinogen I and gastrin.

The laboratory diagnosis of vitamin B12 deficiency is established in accordance with the following criteria:

  1. serum vitamin B12 levels < 150 pmol/L (< 200 pg/mL) with clinical features and/or hematological anomalies related to vitamin B12 deficiency
  2. serum vitamin B12 levels < 150 pmol/L on two separate occasions .
  3. serum vitamin B12 levels < 150 pmol/L and total serum homocysteine levels > 13 μmol/L or methylmalonic acid levels > 0.4 μmol/L (in the absence of renal failure and folate and vitamin B6 deficiencies).
  4. serum holotranscobalamin levels < 35 pmol/L. Immune thrombocytopenia Primary immune thrombocytopenia (ITP), previously called idiopathic thrombocytopenic purpura and autoimmune thrombocytopenic purpura.ITP has been redefined as "an autoimmune disorder characterized by isolated thrombocytopenia (peripheral blood platelet count 100 × 109/L) in the absence of other causes or disorders that may be associated with thrombocytopenia.

Primary ITP is associated with congenital or acquired immune disorders, leading to an autoimmune response against platelets or megakaryocytes and characterized because it is not associated with other alterations.

Gastric MALT lymphoma Gastric MALT lymphoma is a rare form of non-Hodgkin lymphoma that affects B lymphocytes and typically develops in lymphoid tissue associated with mucous membranes and rarely in lymph nodes. It represents approximately 5% of all diagnosed non-Hodgkin lymphomas.

The mechanisms by which H. pylori produces the appearance of a lymphoma similar to gastric carcinogenesis has not been fully clarified, but it is likely that environmental, host, and bacterial-related factors must be involved.H. pylori infection leads to development of MALT lymphoma and can take the following course. First, the infection gives rise to a lymphocyte response that conditions a polyclonal B lymphocyte response and MALT formation through antibody production. Then, different lymphocyte populations would maintain the response provoked by the bacteria. In the polyclonal MALT proliferation, a monoclonal population of B-cells could appear and accumulate cytogenetic changes such as translocations, mutations, microsatellite instabilities, eventually evolving into a low-grade MALT lymphoma that is dependent on H. pylori-related antigen stimuli. Finally, new cytogenetic changes such as translocations, suppressor gene deactivation (p53 and p16, among others), and c-myc activation would make this neoplastic population of monoclonal B-cells escape from its dependence on T lymphocytes and H. pylori antigens and favor its transformation into a high-grade lymphoma. As a result of this sequence of events, a low- or high-grade lymphoma would ultimately develop.

UNRECOGNIZED HEMATOLOGIC MANIFESTATIONS This group includes autoimmune neutropenia, antiphospholipid syndrome, plasma cell dyscrasia including monoclonal gammopathy of undetermined significance and multiple myeloma.

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03629587
Study groupRoleWhat they receive
Patients presented H pylori positiveUpper endoscopy, Gastric biopsy, CBC, VITAMIN B12 level, iron studys, folic acid level, bone marrow aspirate
Patients with H pylori negativeUpper endoscopy, Gastric biopsy, CBC, VITAMIN B12 level, iron studys, folic acid level, bone marrow aspirate

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Upper endoscopy

    To demonstrate infection of H PyloruPylorifohistopathological examination

    Measured: 2 year

Secondary outcomes (4)
  1. Complete blood count

    to assess type of anemia and hematological affection

    Measured: 2 year

  2. Iron studies

    To assess iron deficiency anemia

    Measured: 2 year

  3. Vitamin B 12 level and folic acid level

    To demonstrate level of vitamin B12

    Measured: 2 year

  4. Bone marrow aspiration

    To determine other causes of bone marrow affection

    Measured: 2 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Aug 2018
  2. Study start27 Sep 2016
  3. Primary completion1 Aug 2018
  4. Study completion8 Aug 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03629587
Sponsor's protocol ID
H pylori
Status last verified
Aug 2018
First submitted
15 Jul 2018
Last updated
14 Aug 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Fischbach W, Malfertheiner P. Helicobacter Pylori Infection. Dtsch Arztebl Int. 2018 Jun 22;115(25):429-436. doi: 10.3238/arztebl.2018.0429.

    PubMed 29999489
  • Martinson HA, Shelby NJ, Alberts SR, Olnes MJ. Gastric cancer in Alaska Native people: A cancer health disparity. World J Gastroenterol. 2018 Jul 7;24(25):2722-2732. doi: 10.3748/wjg.v24.i25.2722.

    PubMed 29991877
  • Fukuda T, Asou E, Nogi K, Yasuda M, Goto K. Association between Helicobacter pylori infection and platelet count in mice. Exp Anim. 2018 Nov 1;67(4):487-492. doi: 10.1538/expanim.18-0004. Epub 2018 Jun 7.

    PubMed 29877197
  • Best LM, Takwoingi Y, Siddique S, Selladurai A, Gandhi A, Low B, Yaghoobi M, Gurusamy KS. Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database Syst Rev. 2018 Mar 15;3(3):CD012080. doi: 10.1002/14651858.CD012080.pub2.

    PubMed 29543326
  • Barbosa AMC, Ribeiro RA, Silva CISM, Cruz FWS, Azevedo OGR, Pitombeira MHDS, Braga LLC. Platelet count response to Helicobacter pylori eradication for idiopathic thrombocytopenic purpura in northeastern Brazil. Hematol Transfus Cell Ther. 2018 Jan-Mar;40(1):12-17. doi: 10.1016/j.bjhh.2017.09.005. Epub 2017 Nov 24.

    PubMed 29519366
  • Kim H, Lee WS, Lee KH, Bae SH, Kim MK, Joo YD, Zang DY, Jo JC, Lee SM, Lee JH, Lee JH, Kim DY, Ryoo HM, Hyun MS, Kim HJ; CoOperative Study Group A for Hematology (COSAH). Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia. Ann Hematol. 2015 May;94(5):739-46. doi: 10.1007/s00277-014-2268-9. Epub 2014 Dec 13.

    PubMed 25501820
  • Papagiannakis P, Michalopoulos C, Papalexi F, Dalampoura D, Diamantidis MD. The role of Helicobacter pylori infection in hematological disorders. Eur J Intern Med. 2013 Dec;24(8):685-90. doi: 10.1016/j.ejim.2013.02.011. Epub 2013 Mar 21.

    PubMed 23523153
  • Jafarzadeh A, Akbarpoor V, Nabizadeh M, Nemati M, Rezayati MT. Total leukocyte counts and neutrophil-lymphocyte count ratios among Helicobacter pylori-infected patients with peptic ulcers: independent of bacterial CagA status. Southeast Asian J Trop Med Public Health. 2013 Jan;44(1):82-8.

    PubMed 23682441

Questions about this trial

What is this clinical trial studying?

An observational study of H Pylori Infection, run by Assiut University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Upper endoscopy (time frame: 2 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03629587, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in